Telesis Bio Balance Sheet Health
Financial Health criteria checks 4/6
Telesis Bio has a total shareholder equity of $9.9M and total debt of $5.3M, which brings its debt-to-equity ratio to 53.1%. Its total assets and total liabilities are $52.7M and $42.8M respectively.
Key information
53.1%
Debt to equity ratio
US$5.28m
Debt
| Interest coverage ratio | n/a |
| Cash | US$10.21m |
| Equity | US$9.95m |
| Total liabilities | US$42.78m |
| Total assets | US$52.73m |
Recent financial health updates
Recent updates
The Market Lifts Telesis Bio, Inc. (NASDAQ:TBIO) Shares 38% But It Can Do More
Apr 17
Codex DNA GAAP EPS of -$0.50, revenue of $5.7M; raises FY22 guidance
Aug 09Codex DNA, Inc. (NASDAQ:DNAY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 25Pfizer's Codex DNA Deal Hints At Lucrative Pivot To mRNA - Keep An Eye On This Space
Jan 06Codex: Synthetic DNA/mRNA Instrument Developer Holds Impressive Upside In 2021
Sep 24Financial Position Analysis
Short Term Liabilities: TBIO's short term assets ($15.2M) exceed its short term liabilities ($8.0M).
Long Term Liabilities: TBIO's short term assets ($15.2M) do not cover its long term liabilities ($34.8M).
Debt to Equity History and Analysis
Debt Level: TBIO has more cash than its total debt.
Reducing Debt: Insufficient data to determine if TBIO's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TBIO has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: TBIO is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.